Latest Australian Taxation News

Recce Pharmaceuticals progresses its Phase 3 diabetic foot infection trial in Indonesia, reports promising preclinical data for inhaled RECCE 327, and secures significant R&D funding and patent protection.

Careteq Limited reported a disciplined operating cash flow in Q2 FY26 with strong growth in its Embedded Health Solutions segment and ongoing resolution of an ATO tax incentive dispute.

Latrobe Magnesium has resolved a critical manufacturing defect at its Demonstration Plant, enabling Magnesium Oxide production to resume, while securing key financial support for its commercial expansion plans.

Noxopharm has successfully completed dosing in its HERACLES clinical trial for SOF-SKN™, demonstrating strong safety and tolerability. The company also secured a new overseas partnership and its first US patent for the Sofra platform.

Harvest Technology Group reports improved first-half FY26 financials alongside strategic defense sector expansions, including new reseller agreements and NATO engagements.

Bio-Gene Technology Limited reports strong progress in advancing its Flavocide® and Qcide® insecticidal platforms, backed by US Department of Defense funding and key organic certification in the US.

Indiana Resources has reported significant drilling results at its Minos Gold Project, including high-grade gold intersections up to 71 g/t, while also resolving a longstanding dispute with Tanzania. The company bolsters its exploration team and awaits assay results from nearby prospects.

SenSen Networks has reported record cash receipts for the first half of FY26, driven by strong sales momentum in North America and Australia, alongside innovative product deployments.

Epiminder Limited has successfully listed on the ASX, raising $125 million to commercialise its FDA-approved Minder device. The company has initiated the first US implant and secured five leading medical centres for its DETECT study.

BlackRock Investment Management (Australia) Limited has announced the distribution schedule for its Australian iShares ETFs, with key dates spanning early to mid-February 2026. Investors are reminded to update details and consider the Distribution Reinvestment Plan ahead of the record date.

BCAL Diagnostics has launched its Avantect pancreatic and ovarian cancer tests in Australia, alongside expanding clinical data and establishing a national registry for its BREASTESTplus breast cancer test.

BlackRock Investment Management (Australia) Limited has announced the Distribution Reinvestment Plan (DRP) prices for several Australian-domiciled iShares ETFs for the December 2025 distribution period, providing key details for investors opting into reinvestment.